BASF Corp. and Oxidium Technologies LLC announced an agreement under which Oxidium will acquire BASF’s Aseptrol® technology portfolio. The terms of the transaction were not disclosed.
Originally acquired by BASF from Engelhard in 2006, the Aseptrol chlorine dioxide product line is widely used in applications such as water purification, disinfection, and dental line cleaning.
Through this strategic step, BASF aims to sharpen its portfolio and support growth in prioritized market segments in Home Care and Industrial & Institutional Cleaning Solutions, while Oxidium Technologies LLC deploys the Aseptrol platform across new industries, sectors, and use cases.
“Consistent with our ‘Winning Ways’ strategy, we are proactively optimizing our portfolio and sharpening our priorities,” said Gisela Pinheiro, Senior Vice President, Home Care and Industrial & Institutional Cleaning at BASF. “With Oxidium as a committed, innovation‑oriented owner, the business will be further developed and positioned to realize its full potential.”
Tim Hidell, Co-Founder and CEO of Oxidium Technologies and Quip Laboratories, added: “Bringing Aseptrol into Oxidium gives us the platform to expand this technology well beyond its current footprint. Our distribution partners — led by Quip Laboratories, Aseptrol’s largest — serve diverse markets today, and that foundation is what makes what comes next possible.”
All existing Aseptrol product formulations, labeling, and regulatory approvals remain unchanged, and customers should experience no interruption in supply or support.